Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention Of Venous Thromboembolism
Nov 1, 2014, 00:00 AM
10.1016/j.jval.2014.08.1358
https://www.valueinhealthjournal.com/article/S1098-3015(14)03288-4/fulltext
Section Title :
Disease-Specific Studies
Section Order :
844
First Page :
A475
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)03288-4&doi=10.1016/j.jval.2014.08.1358